ArticleAnnual review of biomedical engineering2021
Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers.
Article in Annual review of biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery.Nature communications · 2024Pooled it
- CD-73 blocking black phosphorus nanosheets hitchhiked on erythrocytesMaterials today. Bio · 2026Article
- Shear-Responsive Red Blood Cell Carriers for Targeted Drug Delivery to Constricted Arteries.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Biomimetic Targeted Drug Delivery for Liver Failure in Abdominal Sepsis: Focus on Autologous Erythrocyte Ghosts.International journal of molecular sciences · 2026Review
- In vivo metabolic tagging and targeting of circulating red blood cells.Nature communications · 2026Article
- Adherence of traffic-related particles to human red blood cellsERJ open research · 2026Article
- From Inflammation to Targeted Therapy: Leveraging Neutrophil, Platelet, RBC, and Macrophage Biology for Nanocarrier in Atherosclerosis.Current atherosclerosis reports · 2026Review
- NanoBondy Reaction through NeissLock Anhydride Allows Covalent Immune Cell Decoration.Bioconjugate chemistry · 2026Article
- Stimuli-Responsive Biomimetic Nanomedicines for Targeted Therapy in Ischemic Stroke: Design Principles, Preclinical Evidence and Translational Challenges.International journal of nanomedicine · 2026Review
- Smart Cells Against Cancer: Advances in Cell-Based Drug Delivery and Diagnostics.Pharmaceutics · 2025Review
- Lipid and polymeric nanocarriers for siRNA delivery to the brain.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- Red blood cell-hitchhiking fluorescent probe to promote intraoperative diagnosis of human ovarian tumor.Science advances · 2025Article
- Multiscale red blood cell hitchhiking for targeted deep tissue gene delivery in lungs.Nature communications · 2025Article
- Split NeissLock with Spy-Acceleration Arms Mammalian Proteins for Anhydride-Mediated Cell Ligation.ACS chemical biology · 2025Article
- Article
- Cell-Based Drug Delivery Systems: Innovative Drug Transporters for Targeted Therapy.International journal of molecular sciences · 2025Review
- Nanomaterial-based encapsulation of biochemicals for targeted sepsis therapy.Materials today. Bio · 2025Review
- Precision-Guided Stealth Missiles in Biomedicine: Biological Carrier-Mediated Nanomedicine Hitchhiking Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Cellular determinants influence the red blood cell adsorption efficiency of poly(amine-Science advances · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Red blood cell (RBC) hitchhiking is a method of drug delivery that can increase drug concentration in target organs by orders of magnitude. In RBC hitchhiking, drug-loaded nanoparticles (NPs) are adsorbed onto red blood cells and then injected intravascularly, which causes the NPs to transfer to cells of the capillaries in the downstream organ. RBC hitchhiking has been demonstrated in multiple species and multiple organs. For example, RBC-hitchhiking NPs localized at unprecedented levels in the brain when using intra-arterial catheters, such as those in place immediately after mechanical thrombectomy for acute ischemic stroke. RBC hitchhiking has been successfully employed in numerous preclinical models of disease, ranging from pulmonary embolism to cancer metastasis. In addition to summarizing the versatility of RBC hitchhiking, we also describe studies into the surprisingly complex mechanisms of RBC hitchhiking as well as outline future studies to further improve RBC hitchhiking's clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.